A detailed history of Voya Investment Management LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 181,919 shares of IDYA stock, worth $6.39 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
181,919
Previous 219,957 17.29%
Holding current value
$6.39 Million
Previous $7.83 Million 1.99%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$34.2 - $47.13 $1.3 Million - $1.79 Million
-38,038 Reduced 17.29%
181,919 $7.98 Million
Q4 2023

Feb 14, 2024

SELL
$24.59 - $35.83 $1.75 Million - $2.55 Million
-71,119 Reduced 24.43%
219,957 $7.83 Million
Q3 2023

Nov 14, 2023

BUY
$21.07 - $29.77 $144,308 - $203,894
6,849 Added 2.41%
291,076 $7.85 Million
Q2 2023

Aug 14, 2023

BUY
$13.33 - $25.53 $3.57 Million - $6.84 Million
268,012 Added 1652.86%
284,227 $6.68 Million
Q4 2022

Feb 14, 2023

BUY
$14.47 - $18.17 $22,124 - $27,781
1,529 Added 10.41%
16,215 $294,000
Q3 2022

Mar 03, 2023

SELL
$9.24 - $15.79 $14,127 - $24,142
-1,529 Reduced 9.43%
14,686 $219,000
Q3 2022

Nov 14, 2022

BUY
$9.24 - $15.79 $10,875 - $18,584
1,177 Added 8.71%
14,686 $219,000
Q2 2022

Aug 15, 2022

BUY
$8.28 - $13.88 $5,696 - $9,549
688 Added 5.37%
13,509 $186,000
Q4 2021

Feb 14, 2022

SELL
$20.95 - $26.88 $2.22 Million - $2.84 Million
-105,798 Reduced 89.19%
12,821 $303,000
Q3 2021

Nov 15, 2021

BUY
$17.26 - $27.08 $1.86 Million - $2.91 Million
107,570 Added 973.57%
118,619 $3.02 Million
Q2 2021

Aug 16, 2021

BUY
$17.76 - $24.83 $196,230 - $274,346
11,049 New
11,049 $232,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.69B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.